Depomed Poised for a Run – Zacks Tale of the Tape
Source: http://www.zacks.com/stock/news/14653/Depomed+Poised+for+a+Run+-+Zacks+Tale+of+the+TapePosted on Wednesday, September 10th, 2008 | In Stocks to Watch
Contributed by: Zacks Market Commentaries (http://www.zacks.com/) -
Depomed, Inc. (DEPO) has risen more than 32% in the last three months to trade near its 52-week high of $4.52. Its deal with CVS Caremark (CVS) can help in expanding distribution of diabetes drug Glumzeta. The Zacks #1 (Strong Buy) company already has two successful drugs in the market, and looks attractive to shareholders at its current price. Analysts expect a loss of $0.50 per share in 2008, less than their prior forecast of $0.89.
“DEPO” Free Stock Analysis: Buy? Sell? Hold?
“CVS” Free Stock Analysis: Buy? Sell? Hold?
Zacks Investment Research
Last 5 posts by Zacks Market Commentaries
- Settlement in Xerox-ACS Merger - Analyst Blog - November 24th, 2009
- Citi Expects Strong Economic Growth - Analyst Blog - November 24th, 2009
- Downgrading Expedia to Neutral - Analyst Blog - November 24th, 2009
- Foot Locker Misses Expectations - Analyst Blog - November 24th, 2009
- Patni Exceeds Estimates - Analyst Blog - November 24th, 2009
 About Zacks Market Commentaries (http://www.zacks.com/)
Zacks Market Commentaries |
No recommendations, either expressed or implied, are being made to buy, sell, hold or short any of the mentioned stocks. No legal, tax or accounting advice is expressed or implied. Always contact your attorney, CPA, or tax advisor before acting on any legal or tax issues. StraightStocks.com is not responsible for the content, products, or services of any of the advertisers on this site. StraightStocks.com receives compensation from advertisers on this blog. Services and products referred to herein are trademarks, registered trademarks, servicemarks, and/or registered servicemarks of their respective trademark or servicemark owners.